方法证据记录
Risk-adjusted Phase II clinical trial
A risk-adjusted Phase II clinical trial is an early-phase efficacy design that incorporates patient baseline risk strata — such as disease severity, prognostic score, or comorbidity burden — directly into the trial's stopping rules and sample size calculations. By conditioning response targets and futility/efficacy thresholds on risk group membership, the design avoids the bias that arises when a new therapy is evaluated in a population whose prognostic mix differs from the historical control on which the null hypothesis was based.
源记录
引文逐字复制自方法源记录。这些引文不代表任何层级的验证。
Risk-Adjusted Phase II Clinical Trial Design
分类方法记录 · process-pipeline / epidemiology
- Thall, P. F., & Simon, R. (1994). Practical Bayesian guidelines for phase IIB clinical trials. Biometrics, 50(2), 337–349. · DOI 10.2307/2533377
- Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10(1), 1–10. · DOI 10.1016/0197-2456(89)90015-9
精选声明
声明已持久化到证据分类账中，每个声明都有自己的评估。
尚无精选声明
当分类账中没有声明时，此视图不会自行创建声明评估。
相关方法
从方法图中生成，显示为机器建议的关系 — 不推断任何证据声明。
尚无相关方法
生成的关联图对此方法没有传出的关联。